OKYO Pharma Limited Dossier
Qualitative Analysis
Business overview
OKYO Pharma Ltd is a clinical-stage biopharmaceutical company focused on the discovery and development of novel molecules to treat inflammatory eye diseases and ocular pain. The company's primary asset is urcosimod (formerly OK-101), a first-in-class lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor. Urcosimod is designed to address both inflammation and neuropathic corneal pain (NCP), representing a major therapeutic candidate in ophthalmology where there are currently no FDA-approved therapies for NCP. OKYO Pharma operates primarily in the United States and the United Kingdom.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the clinical development of lead candidate urcosimod (formerly OK-101) for neuropathic corneal pain (NCP) following positive Phase 2a proof-of-concept results.
Expected impact: Establish optimal registration dosing and generate pivotal-grade efficacy data for a condition with no current FDA-approved therapies.
Appointment of Robert J. Dempsey as Chief Executive Officer to drive the company's next growth phase, leveraging his extensive experience in global ophthalmology.
Expected impact: Brings deep commercialization and launch expertise (e.g., Xiidra, Restasis) as OKYO transitions from proof-of-concept to registration-focused clinical stages.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Replaced B. Riley Securities Inc. as the sales agent, allowing OKYO to access capital markets efficiently and opportunistically to fund clinical programs.
Terms: Enables the sale of common shares directly into the market from time to time at prevailing market prices.